Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus CEPHALOTHIN SODIUM W DEXTROSE IN PLASTIC CONTAINER.
CEFTRIAXONE SODIUM vs CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible gram-positive and some gram-negative bacteria.
1-2 g IV/IM every 12-24 hours; maximum 4 g/day.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life is 5.8-8.7 hours in adults with normal renal and hepatic function. In neonates, half-life is prolonged (up to 16 hours). In patients with renal impairment, half-life increases to 12-18 hours; in hepatic impairment, it may be 15-20 hours. Dose adjustment is not typically required unless both renal and hepatic impairment are present.
30-60 minutes in normal renal function; prolonged to 2-8 hours in severe renal impairment (CrCl <10 mL/min).
Ceftriaxone is eliminated 33-67% unchanged in urine via glomerular filtration and tubular secretion, and the remainder is excreted in feces (primarily as microbiologically inactive metabolites) via biliary secretion. Biliary excretion accounts for approximately 35-45% of total clearance.
Primarily renal (60-70% unchanged) via glomerular filtration and tubular secretion; minor biliary (5-10%) and fecal (<1%) elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic